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Hemoblobin A
1
c is the most important parameter for the monitoring of metabolic control of patients with 
diabetes mellitus. The purpose of this study was to adapt the Mono S method to a conventional HPLC 
system, allowing highly selective HbA
1
c determination without the acquisition of kits or the use of dedicated 
systems The results obtained were compared to the Tinaquant® immune turbidimetric method and the Bio-
Rad Variant® chromatographic method. The developed method presented intra-study precision (C.V. %) of 
1.39-3.65 and inter-study precision (C.V. %) of 2.80-3.02%. The determination coefficients among methods 
were: HPLC Mono S x Tinaquant®: r2: 0.9856 (n=60) and HPLC Mono S x HPLC Bio-Rad Variant®: r2: 
0.9806 (n=16). A conversion equation between HPLC Mono S and Bio-Rad Variant® was calculated allowing 
yielding comparable and interchangeable values. The HPLC Mono-S is a precise, low-cost method which 
yields similar values to the Bio-Rad Variant® method on conventional HPLC equipment.
Uniterms: High performance liquid chromatography. Mono S/method. Hemoglobin/A
1
c. Hemoglobin/
variants.
A hemoglobina A
1
c é o parâmetro laboratorial mais importante no monitoramento do controle metabólico de 
pacientes portadores de diabetes melito. Dentre as metodologias existentes para a quantificação desta fração 
de hemoglobina, a cromatografia líquida de alta eficiência (CLAE) baseada em troca catiônica apresenta a 
melhor precisão, sendo o método de escolha. O objetivo deste trabalho foi adaptar o método Mono S a um 
sistema de CLAE convencional permitindo a disponibilidade da determinação altamente seletiva de Hb A
1
c 
sem a aquisição de kits e comparar os resultados obtidos com o método imunoturbidimétrico Tinaquant® 
(Roche®) e com o método de cromatografia líquida Bio-Rad Variant®. O método desenvolvido apresentou 
precisão intra-ensaio de 1,39-3,65% e inter-ensaio de 2,80-3,02%. Os coeficientes de determinação entre 
os métodos foram: CLAE Mono S x Tinaquant®: r2 = 0,9856 (n=60) e CLAE Mono S x Bio-Rad Variant®: 
r2 = 0,9806 (n=16). Não foram observadas diferenças entre CLAE Mono S e Bio-Rad Variant® através 
de gráfico de Bland-Altman e regressão de Passing-Bablok. Foi obtida uma equação de conversão entre 
os valores do método teste e os valores obtidos por métodos rastreáveis ao National Glycohemoglobin 
Standardization Program (NGSP), permitindo a obtenção de valores comparáveis e intercambiáveis entre 
as metodologias com o uso de instrumentos convencionais de CLAE e com custo reduzido.
Unitermos: Cromatografia líquida de alta eficiência. Mono S/método. Hemoglobina/A
1
c. Hemoglobina/
variantes.
INTRODUCTION
Hemoglobin A
1
c (Hb A
1
c) is the most important 
laboratory parameter in monitoring metabolic control 
of patients with diabetes mellitus (Sacks et al., 2002). 
The quantity of HbA
1
c reflects the mean blood glucose 
concentration over the two or three preceding months and 
is therefore an independent parameter of carbohydrate 
metabolism. (Miedema, 2004). In 1993, The Diabetes 
Control and Complications Trial Research Group (DCCT) 
proposed target levels of Hb A
1
c for diabetic control in 
order to minimize chronic complications characteristic of 
the disease such as retinopathy, nephropathy, and cardio-
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vascular disease. These values have since become widely 
used in clinical practice.
In view of the high worldwide incidence of diabetes 
mellitus and the complications resulting from uncontrolled 
circulating glucose levels, there is great demand for Hb A
1
c 
determinations in clinical samples. As this parameter is 
used for long term control of patients, it is fundamental that 
the method used has a very high degree of reproducibility. 
In addition, in order to allow the use of universally agre-
ed therapeutic target levels for this parameter, accuracy 
becomes paramount, given that the results of this test are 
standardized internationally through a variety of different 
national schemes.
The three nationally accepted methods for determi-
nation of Hb A
1
c, based on cation exchange methods, are: 
the National Glycohemoglobin Standardization Program 
(NGSP) from the United States; Japanese Diabetes Society 
(JDS) from Japan, and the Mono S method from Sweden. 
Recently, the International Federation of Clinical Chemis-
try and Laboratory Medicine (IFCC) introduced a highly 
selective international reference standard for Hb A
1
c, ba-
sed on liquid chromatography associated in tandem with 
mass spectroscopy (LC-MS/MS), or alternatively, a dual 
method which involves initial purification of the fraction 
of Hb A
1
c using high performance liquid chromatography, 
followed by determination using capillary electrophoresis 
(CE) (Jeppsson et al., 2002). The IFCC reference method 
was extensively compared with national Standards, called 
Designated Methods of Comparison (DMC). Based on these 
studies, master equations for conversion between DMC 
and the IFCC reference standard were established and have 
shown high inter-laboratory reproducibility (Hoelzel et al., 
2004). The same study showed a high correlation among 
the DMCs, despite differences in specificities, allowing 
conversion of analytical findings among different methods. 
The DMC used by the NGSP, which served as a 
basis for the therapeutic targets presently used for Hb A
1
c 
determination by the DCCT, were initially described by 
Trivelli et al. (1971) and used a Bio-Rex 70 cation exchan-
ge column (produced by Bio-Rad). However, later studies 
found this separation technique to be limited and revealed 
that the peak quantified as Hb A
1
c included a high pro-
portion of other forms of hemoglobin (Miedema, 2004). 
The DMC of JDS also used a dedicated cation exchange 
chromatography system produced by Tosoh, which offered 
superior selectivity compared to the NGSP method. Both 
methods used dedicated, highly automated equipment for 
analyzing Hb A
1
c and related compounds.
The Swedish DMC used a Mono S column, produ-
ced by Pharmacia (now GE HealthCare) and was initially 
proposed by Jeppsson et al. in 1986. The Mono S column 
is a strong, methyl sulphonate, based cation exchanger, 
with an extremely uniform granule distribution and com-
pared to the other DMCs, yields values closer to the IFCC 
reference method (Hoelzel et al., 2004). Values found by 
the Mono S method are always lower than those derived 
from the NGSP and JDS methods, whereby a master 
equation of the IFCC values for Mono S show higher 
slope and lower intercept, indicating improved chromo-
graphic separation and lower proportion of non-Hb A
1
c 
components.
The Mono S method was originally developed 
for Fast Protein Liquid Chromatography (FPLC) units 
constructed to analyze proteins, and characterized by 
operating under pressures significantly lower than those 
of conventional HPLC units. Although Hb A
1
c determi-
nation on traditional HPLC systems had been previously 
reported (Ellis et al., 1984; Brunnekreeft, Eidhof, 1993; 
Turpeinen et al., 1995), the unconverted values which 
resulted tended to limit clinical application, especially in 
view of the difficulty in comparing Hb A
1
c values against 
standardized reference values for diabetes mellitus con-
trol. We found no studies which employed the Mono S 
column for Hb A
1
c determination on HPLC systems, 
equipment that can be used for a broad range of other 
clinical analyses.
At present, the determination of glycosylated he-
moglobin in Brazilian clinical laboratories is usually done 
with the dedicated Bio-Rad Variant® chromatography 
unit. The objective of this study was to develop a HPLC 
method for determining Hb A
1
c using a Mono S column 
which could enable highly selective determination of Hb 
A
1c
 and represent a lower cost alternative that needs no 
commercial kits.
MATERIAL AND METHODS
Solutions, reagents and controls
Sodium maleonate and lithium chloride were ac-
quired from Vetec Química Fina Ltda (Rio de Janeiro, 
Brazil). Sodium azide and mono basic potassium phos-
phate were purchased from Cromato Produtos Químicos 
Ltda (Diadema, Brazil), and Triton X-100 from Casa de 
Química (Diadema, Brazil). Citric acid was obtained from 
Dinâmica Química Contemporânea (Diadema, Brazil). 
Water was obtained by distillation and deionization and 
further purified using Elga Pure Lab Ultra SC from Elga 
Labwater (Lane End, United Kingdom).
Mobile phase A was prepared by diluting 3.05 g of 
sodium malonate and 0.2 g of sodium azide in 1 L of puri-
fied water. Mobile phase B was made by diluting 3.05 g 
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of sodium malonate, 0.2 g of sodium azide, and 12.85 g 
of lithium chloride in 1 L of purified water. The mean 
pH of both mobile phases was 5.7. The mobile phases 
were filtered with a 0.45 µm cellulose acetate membrane 
(Shleicher and Schuell, Germany). A hemolyzing solution 
was prepared by diluting 0.39 g of citric acid and 0.78 g of 
monobasic sodium phosphate in 100 mL of purified water, 
after adding 94 µL of Triton X-100. The mean pH of the 
hemolyzing solution was 5.4. The control for Hb A
1
c was 
Lyphochek Diabetes Control Levels 1 and 2 provided by 
Bio-Rad (Irvine, U.S.A), where mean values obtained 
from the Bio-Rad Variant were 5.6% (range 4.5-6.7%) 
and 9.2% (range 8.4-10.0%). This commercial control also 
contains Hb F and Hb A
0, 
although values are not declared 
quantitatively. Control samples for Hb F, S and C were 
obtained from Interscientific (Hollywood, U.S.A), with 
mean values on cellulose acetate electrophoresis of 21, 
17 and 13%, respectively.
Chromatographic analysis
The chromatographic system was a quaternary 
system of LC-10AT pumps, a SCL-10-A control module, 
CTO10-AS column oven, SIL-10AF auto-injector and 
SPD-M10A diode arrangement detector (DAD) and Class 
VP 6.13 SP2 control program (Shimadzu, Kyoto, Japan). 
Separation was done in a 10 mm spherical phase column 
based on polystyrene cross linked with divinylbenzene, 
with methylsulphonate cation exchange groups in a glass 
tube of 5 by 50 mm internal diameter (Mono S GL 5/50) 
from GE Healthcare (Uppsala, Sweden). Chromatograms 
were monitored at 415 nm. The initial elution consisted of 
80% mobile phase A and 20% mobile phase B, with the 
following gradient program: 50% B until 3.9 minutes; 
75% B up to 4.26 minutes, 100% B until 4.58 minutes, 
and maintaining this proportion until a total of 11 minutes 
had elapsed, with a return to initial conditions in 11.8 
minutes, which were maintained for a total elapsed time of 
13 minutes. The equilibrium time between analyses was 2 
minutes, and total chromatographic analysis time was 15 
minutes. The samples were eluted at a rate of 1 mL/min 
and the column was kept at 30 ºC during analyses. The 
proportion of normal hemoglobin fraction (Hb F, Hb A
1
c 
and Hb A
o)
, as well as the hemoglobin variants (Hb S and 
Hb C), were calculated as a percentage of the area of their 
peaks in relation to the total area of hemoglobin peaks on 
the chromatogram.
Sample preparation
Venous blood samples were collected in EDTA 
coated tubes and maintained at 4 °C until analysis, which 
occurred within a maximum of 7 days. Polypropylene 
micro tubes were used, containing 14 µL of whole blood 
and 700 µL of hemolyzing solution. This mixture was 
homogenized in a vortex agitator for 10 seconds, and then 
maintained in a water bath at 37 °C for 30 minutes in order 
to eliminate the labile fraction of Hb A
1
c. Subsequently, 
the sample was centrifuged for 5 minutes in a micro cen-
trifuge maintained at 4 ºC, with a velocity of 11,000 g. 
A 10 µL aliquot of the supernatant was injected into the 
HPLC-DAD system. 
Quality control
Venous blood samples from three patients (Hb 
A
1
c of 4.3, 5.9 and 10.2 %) were processed using the 
described method, in triplicate, on five different days, 
using the conversion equation for NGSP aligned values. 
The percentages of HbA
1
c found for each patient were 
analysed using ANOVA (Analysis of Variance Test) with 
the days as a grouped variable, enabling calculation of 
intra and inter study precision. Precision was given as 
a coefficient of percentage variation (C.V%). Accuracy 
was calculated by comparing results of the analysis of 16 
samples using the test method to results using the Bio-Rad 
Variant® method, and expressed as a percentage of the va-
lue obtained using the reference method. Additionally, 22 
sample replicas of commercial quality controls for Hb A
1
c 
(Lyphochek Diabetes Control Levels 1 and 2) were tested 
and the results obtained compared with those claimed by 
the manufacturer. 
Comparison with other methods
Venous blood samples from 60 patients were pro-
cessed by the test method and by the immunoturbidity 
method (Tinaquant®, Roche), calibrated according to 
IFCC/NGSP. A linear regression curve for the obtained 
values was calculated, in which the % Hb A
1
c obtained 
by the present method was represented on the y (ordinal) 
axis, and the immunoturbidity values on the x axis (abscis-
sa). Samples containing other hemoglobin variants were 
excluded. Correlation among the evaluated methods was 
determined using the correlation coefficients (r2). Linear 
regression analysis was used to convert HPLC values to 
NGSP-aligned ranges. Calculations were performed using 
Microsoft Excel® (Microsoft Corporation, U.S.A). 
In addition, a further 16 blood samples were evalu-
ated using both the study method and a dedicated HPLC 
system (Bio-Rad Variant®). The Hb A
1
c % values found 
using the test method and converted to NGSP values as 
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described above, were compared with the values obtained 
using the dedicated Bio-Rad Variant® system by means 
of Bland and Altman graphics (Bland, Altman, 1986) 
and Passing-Bablok regression (Passing, Bablok, 1983). 
These methods do not depend upon use of methods whi-
ch classify variables as dependent or independent with 
calculation of slope and intercept and their respective 
confidence intervals. 
RESULTS AND DISCUSSION
Chromatographic separation and detection
The composition of the mobile phase was the same 
as used by Jeppson et al (1986) in a HPLC system; with the 
elution conditions and modifying gradients modified for 
their HPLC system, and optimization of chromatographic 
resolution. The total analysis time was 15 minutes, during 
which the separation and quantification of the normal 
hemoglobin fractions (Hb F, Hb A
1
c, Hb A
0
) and variants 
(Hb S and Hb C), occurred with mean retention times of: 
2.9, 3.6, 9.2, 10.1, and 11.8 minutes, respectively. Figure 1 
shows typical control chromatograms for Hb A
1
c
 
and Hb F, 
Hb S and Hb C, as well as one sample for a patient with Hb 
S. The proportions of Hb A
1
c and the other hemoglobins 
were calculated as a percentage of the area of their peaks 
in relation to the total area of all the hemoglobin peaks 
on the chromatogram. At the time of writing, more than 
7,000 samples had been processed using the same Mono 
S column without loss of chromatographic resolution or 
the appearance of interfering peaks. 
This method was developed to routinely measure 
levels of HbA
1
c in the continuing care of patients with 
diabetes mellitus. However, it is also a useful tool for 
screening and measuring levels of hemoglobins F, S and 
C. Heterozygotes or homozygotes with these fractions 
can thus be found when testing for Hb A
1
c. It is important 
to point out that HPLC, given its greater accuracy, is re-
commended over electrophoresis for hemoglobin analysis 
(Fernandes, Domingos, 2006). 
Quality Control
The precision of the test method was evaluated by 
performing triplicate measurements on five different days 
on blood samples from patients with different levels of Hb 
A
1
c%. The intra study variation in precision ranged from 
1.39 to 3.65%, while inter study precision ranged between 
2.80 and 3.02%. The validation parameters were in line 
with published values for bio analytic methods, as listed 
by Shah et al. (2000), and are shown in Tables I and II.
Analysis of commercially available control samples 
of Hb A
1
c using the test method are shown in Table II. Val-
ues obtained were all within recommended intervals, with 
values found to be very close to the central value stated by 
the supplier of the samples. 
FIGURE 1 - Chromatograms monitored at 415 nm. A: Control 
sample of HbA
1
c
 
(9.2%), peak 1: Hb F (0.8%); peak 2: Hb A
1
c
 
(9.2%); peak 3: Hb A
0 
(89%). B: Control sample of hemoglobin 
variants, peak 1: Hb F (17%), peak 3: Hb A
0
 (39%); peak 4: Hb S 
(15%); peak 5: Hb C (11%). C: Patient sample; peak 2: Hb A
1
c
 
(6.8%); peak 3: Hb A
0 
(51%), peak 4: Hb S (38%).
TABLE I - Inter and intra study precision of HbA
1
c determinations 
in patient samples (n=15)
Hb A
1
c
 
(%) 
(mean)
Intra-study 
(C.V. %)
Inter-study 
(C.V. %)
4.3 3.65 2.80
5.9 1.50 2.96
10.2 1.39 3.02
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Hb A
1
c levels based on the total area of the chro-
matogram were found to be very precise and neutralized 
the impact of any variations in the injected volumes. This 
strategy has been used extensively in the determination of 
Hb A
1
c by HPLC, as the inter-study precision is superior 
to those protocols which use calibration curves (Gerlo and 
Gorus, 1997). 
Comparison with other methods
Two comparative studies were done with other 
methods. Tinaquant® immunoturbidimetric method and 
HPLC Mono S methods were used to analyze 60 blood 
samples for Hb A
1
c. Figure 2 shows the correlation 
between the values obtained using these two methods, 
which presented a high coefficient of determination (r2 = 
0.9856), although the values obtained using HPLC Mono 
S were, on average, 76.92% of the values of NGSP. The 
systematically lower values found with the HPLC Mono 
S method corroborated results of earlier studies, which 
indicated its higher specificity (Hoelzel et al., 2004). The 
conversion equation was expressed as: Hb A
1
c
 NGSP
 = (Hb 
A
1
c
Mono S
 + 0.7866)/0.8675. This conversion equation was 
used to transform the HPLC Mono S values to the referen-
ce standard NGSP values. In our comparison study, a clear 
gain in specificity of the chromatography method over the 
immunoturbidity method was found. One of the samples 
evaluated gave markedly discordant Hb A
1
c % values 
between both methods (4.5% on HPLC Mono S versus 
6.8% for Tinaquant®), which could be attributed to a higher 
proportion of Hb S (37.7%), which was readily detected 
by HPLC. The values for this particular sample were not 
included in the calculations for the conversion equation.
The comparison between the test method and the 
Bio-Rad Variant® system showed a high correlation be-
tween the two techniques. Using the conversion equation, 
the coefficient of determination was 0.9806 and absolute 
values were very similar (Figure 4). In this comparative 
study, the HPLC Mono S values, converted to NGSP 
values, showed a mean of 99.0% (range 97-104%) of the 
values found using the Bio-Rad Variant® system. 
Using Bland and Altman graphs (Figure 3), the 
mean difference between the values obtained by the HPLC 
Mono S and the Bio-Rad Variant® was 0.09%, where all 
the values presented differences of between +0.30 and 
-0.70%, in relation to the mean. Differences were also 
distributed randomly around the mean, indicating the 
absence of systematic errors which were proportional to 
% Hb A
1
c values. 
The values obtained using the HPLC Mono S 
and Bio-Rad Variant® methods were compared using 
the Passing-Bablok regression method (Figure 4). All 
values obtained were found to lie within the 95% confi-
dence interval. The regression equation calculated was: 
Hb A
1
c
 Mono S
 = Hb A
1
c
Bio-Rad Variant 
- 0,1. Regression analysis 
for the confidence intervals of the slope (0.9077 – 1.1224) 
and of the intercept (-1.0276 – 0.5654) show that the me-
TABLE II - Results obtained from analyses of control samples 
of HbA
1
c (n=22)
Concentration* 
Hb A
1
c (%)
 Concentration 
ranges found (%)
Mean of 
concentrations 
found (%)
5.6 5.3 – 5.9 5.6
9.2 9.4 – 10.3 9.7
* Median of range provided by the supplier
FIGURE 2 - Comparison between Hb A
1
c% found by HPLC 
Mono S and Tinaquant® Immunoturbidity (n=60).
Mean of HPLC Mono S and Bio-Rad Variant®
HPLC Mono S- Bio Rad Variant®
FIGURE 3 - Bland and Altman Graph comparing results of 
HPLC Mono S with Bio-Rad Variant®.
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thods do not differ by a constant value and that there are 
no proportional differences between the methods. The 
correlation between the data remains linear ( P > 0.10). 
The slight differences between the results obtained 
using HPLC Mono S and the reference Bio-Rad Variant® 
method showed that the results are comparable, and thus 
interchangeable.
A disadvantage of the proposed protocol is the 
chromatographic analysis time, which is greater than that 
of dedicated systems for analyzing Hb A
1
c. However, 
the use of the HPLC systems provides greater flexibility, 
allowing the equipment to be used for other laboratory 
applications. It should be noted that costs are significantly 
reduced using the protocol developed in this study, as all 
the reagents used in the analyses are prepared in-house 
by the laboratory at relatively low cost compared to the 
purchase price of specialized commercial kits. 
CONCLUSIONS
A method was developed for determining Hb A
1
c 
and hemoglobins F, S and C using a HPLC system, em-
ploying a Mono S5/50 GL cation exchange column. The 
method is precise and yields similar values to those of 
IFCC/DCCT. However, the values attained by the method 
are highly correlated with those of the dedicated Bio-Rad 
Variant® system. Besides being a low cost solution, the 
principal advantage of the method studied is the possibility 
of its inclusion in a routine laboratory setting using a high 
performance liquid chromatography system, where this 
same equipment can also be used with other techniques. 
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